RS
FATE icon

R Squared’s Fate Therapeutics FATE Stock Holding History

R Squared’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.2K Buy
18,524
+8,066
+77% +$9.82K 0.01% 462
2025
Q4 		$10.3K Sell
10,458
-7,471
-42% -$8.97K ﹤0.01% 509
2025
Q3 		$22.6K Buy
+17,929
New +$19.3K 0.01% 525
2025
Q1 		– Sell
-600
Closed -$990 – 686
2024
Q4 		$990 Buy
+600
New +$1.51K ﹤0.01% 1514

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's FATE Position: Q1 2026 in Review

R Squared increased its Fate Therapeutics (FATE) stake by 77% in Q1 2026, buying an estimated $9.82K and bringing the position to 18,524 shares worth $22.2K. The position accounts for 0.01% of the portfolio, ranked #462.

R Squared first reported a position in FATE in Q4 2024 and has held it in 4 quarters since. The position peaked at $22.6K in Q3 2025. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • R Squared held 18,524 shares of Fate Therapeutics worth $22.2K as of Q1 2026.
  • R Squared bought 8,066 Fate Therapeutics shares in Q1 2026, an estimated $9.82K.
  • Fate Therapeutics made up 0.01% of R Squared's portfolio in Q1 2026, its #462 holding.
  • R Squared first reported a position in Fate Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • R Squared's Fate Therapeutics position peaked at $22.6K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.